    Barry Quart | Ardea Biosciences , Inc. | ZoomInfo.com










 





Insider Trading - Quart Barry D - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Quart Barry D





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2015-03-02Sale
2015-03-046:52 pm
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
10,000
$13.07
$130,727
42,868(Direct)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-12-21Option Award
2016-12-234:04 pm
N/A2026-12-21
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
310,000
$13
310,000(Direct)
View


2016-07-19Other
2016-07-2008:50 am
N/AN/A
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
837
$18.22
930,277(Direct)
View


2016-07-19Exercise
2016-07-2008:50 am
N/AN/A
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
4,630
$7.2
930,277(Direct)
View


2016-07-19Exercise
2016-07-2008:50 am
N/A2023-05-01
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
4,630
$7.2
930,277(Direct)
View


2016-03-02Exercise
2016-03-0308:01 am
N/AN/A
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
3,472
$7.2
934,907(Direct)
View


2016-03-02Exercise
2016-03-0308:01 am
N/A2023-05-01
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
3,472
$7.2
934,907(Direct)
View


2015-12-28Exercise
2015-12-305:13 pm
N/AN/A
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
2,315
$7.2
938,379(Direct)
View


2015-12-28Exercise
2015-12-305:13 pm
N/A2023-05-01
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
2,315
$7.2
938,379(Direct)
View


2015-12-22Option Award
2015-12-2412:31 pm
N/A2025-12-22
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
250,000
$29.41
250,000(Direct)
View


2015-10-14Exercise
2015-10-1508:02 am
N/AN/A
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
10,000
$7.2
940,694(Direct)
View


2015-10-14Exercise
2015-10-1508:02 am
N/A2023-05-01
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
10,000
$7.2
940,694(Direct)
View


2015-09-29Exercise
2015-09-3008:51 am
N/AN/A
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
14,306
$7.2
950,694(Direct)
View


2015-09-29Exercise
2015-09-3008:51 am
N/A2023-05-01
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
14,306
$7.2
950,694(Direct)
View


2015-08-18Other
2015-08-194:39 pm
N/AN/A
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
2,881
$7.6
965,000(Direct)
View


2015-08-18Exercise
2015-08-194:39 pm
N/AN/A
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
10,000
$7.2
965,000(Direct)
View


2015-08-18Exercise
2015-08-194:39 pm
N/A2023-05-01
Heron Therapeutics Inc
HRTX
Quart Barry DChief Executive OfficerDirector
10,000
$7.2
965,000(Direct)
View


2015-06-22Disposition
2015-06-2310:37 am
N/A2019-07-21
Synageva Biopharma Corp
GEVA
Quart Barry DDirector
1,375
$10.1
0(Direct)
View


2015-06-22Disposition
2015-06-2310:37 am
N/A2020-09-22
Synageva Biopharma Corp
GEVA
Quart Barry DDirector
1,500
$11.35
0(Direct)
View


2015-06-22Disposition
2015-06-2310:37 am
N/A2018-06-26
Synageva Biopharma Corp
GEVA
Quart Barry DDirector
1,375
$20.6
0(Direct)
View


2015-06-22Disposition
2015-06-2310:37 am
N/A2021-12-20
Synageva Biopharma Corp
GEVA
Quart Barry DDirector
8,375
$23
0(Direct)
View


2015-06-22Disposition
2015-06-2310:37 am
N/A2017-06-27
Synageva Biopharma Corp
GEVA
Quart Barry DDirector
1,000
$23.95
0(Direct)
View


2015-06-22Disposition
2015-06-2310:37 am
N/A2023-06-06
Synageva Biopharma Corp
GEVA
Quart Barry DDirector
5,001
$40.32
0(Direct)
View


2015-06-22Disposition
2015-06-2310:37 am
N/A2022-06-27
Synageva Biopharma Corp
GEVA
Quart Barry DDirector
3,750
$40.74
0(Direct)
View


2015-06-22Disposition
2015-06-2310:37 am
N/A2024-06-04
Synageva Biopharma Corp
GEVA
Quart Barry DDirector
7,500
$80.35
0(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 06:23:48 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  











Barry D Quart - Encinitas, CA | Intelius



























Sign In



We found Barry D Quart in Encinitas, CA


Barry D Quart

                                                                           Intelius found that Barry D Quart  is  a male between 60 and 60 years old from Encinitas, CA.  We have connected them to
                9 addresses,
                10 phones,
                and 3 relatives or associates.
         





Also Known As

Barry David Quart


Get Report Now

Age

Barry D Quart is in his 60s

Barry Has Lived In

Encinitas, CA
Las Vegas, NV
Evansville, IN

Barry's Relatives

Kelly Quart
Kristine Quart
Gabrielle Quart







Barry D Quart



Zodiac SignCapricorn



GenderMale



Professional Status
Ardea Biosciences , Inc.



Get Report Now










Want to know more about Barry? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Barry, or use our people search engine to find others.
Get Background Check on Barry D Quart
Get a Criminal Check on Barry D Quart
Get a Public Record Report on Barry D Quart
Get a People Search Report on Barry D Quart


Barry D Quart's Contact Information
Known Cities Lived In
Find out where Barry D Quart has lived as well as Barry D Quart's phone numbers and email addresses.




Barry D Quart Has Lived in 4 States
California Address for Barry D Quart


3273 V***** R** 

Encinitas, CA


Has Lived In

Encinitas, CA
Las Vegas, NV


Get Full Address Report










Phone Numbers Associated with Barry D Quart

(858) ***-**** - Encinitas, CA 
(858) ***-**** - Encinitas, CA 
(858) ***-**** - Encinitas, CA 


Get Full Phone Report



Email Addresses Associated with Barry D Quart

b*******3@***.com
k****t@***.com
k****t@***.com


Get Email Report




Barry D Quart's Education Information
Known Schools Attended
Learn about Barry D Quart's academic history.  Find out which schools Barry D Quart attended, the dates attended as well as the degrees Barry D Quart received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Barry D Quart Has Attended 1 School
Grant High School 1970 – 1974                              


Barry D Quart's Professional Information
Information regarding Barry D Quart's professional history.  Find out previous places Barry D Quart has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Barry D Quart Has Worked at 2 Places
Company: Ardea Biosciences , Inc.
               
Company: Trimeris , Inc.
               
Barry D Quart's Experience
Title: 
               Company: Ardea Biosciences , Inc.
Job Details

Title: 
               Company: Trimeris , Inc.
Job Details

Additional Professional Information on Barry D Quart

 See Barry D Quart's LinkedIn Profile



Barry D Quart's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Barry D Quart


Barry D Quart's known Social Networks And Potential Email Matches

Find all of Barry D Quart's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Barry Quart
Username Matches

                  BarryQuart
                  QuartBarry
                  Barry.Quart
                  Quart.Barry
                  Barry_Quart
                  Quart_Barry
                  Barry-Quart
                  Quart-Barry
                  BQuart
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
B Quart







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.













Barry D. Quart Pharm.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 7:23 AM ET
Biotechnology

Company Overview of Heron Therapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Barry D. Quart Pharm.D.Chief Executive Officer & Director, Heron Therapeutics, Inc.AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 7 different industries.See Board Relationships60$3,772,329As of Fiscal Year 2016
Background

		Dr. Barry D. Quart, Pharm.D., has been the Chief Executive Officer of Heron Therapeutics, Inc. since May 02, 2013. Dr. Quart serves as the Scientific Advisor of Napo Pharmaceuticals, Inc. He served as the Chief Executive Officer and President at Ardea Biosciences, Inc. since December 21, 2006, which was acquired by AstraZeneca PLC in June 2012. He served as General Manager for Americas Region, Kodak's Business Solutions and Services of Eastman Kodak Co. He served as ... the President of Napo Pharmaceuticals Inc. from June 2002 to July 31, 2006 and served as its Chief Scientific Officer until July 31, 2006. He served as the President and Chief Executive Officer of Intrabiotics Pharmaceuticals Inc. since December 22, 2006. He served as Senior Vice President of Pfizer Global Research and Development. He served as Senior Vice President and Head of Drug Development for Agouron Pharmaceuticals Inc., a division of the Warner-Lambert Company, since 1997 and also served as its President of Research and Development. since 1999, where he was instrumental in the development and registration of Viracept, which went from the lab bench to NDA approval in 38 months. Dr. Quart served as Vice President of Regulatory Affairs for Agouron Pharmaceuticals Inc. since joining in 1993. He served as an Executive Director of international regulatory affairs for Bristol-Myers Squibb Company since 1992. Dr. Quart served with Bristol-Myers Squibb for ten years experience in both Clinical Research and Regulatory Affairs, where he was actively involved in the development and registration of nine important drugs, including paclitaxel, didanosine, stavudine and sotalol. Within the newly created Pfizer Global Research and Development Division, he served as Senior Vice President of La Jolla Laboratories. He serves as a Director of NeuroGenetic Pharmaceuticals, Inc. He has been a Director of Ardea Biosciences, Inc. since December 21, 2006, Heron Therapeutics, Inc. since June 2012. Dr. Quart served as a Director of Trimeris Inc. since June 2007 and Director of Synageva Bio Pharma Corp. from June 2007 to June 22, 2015. He served as a Director of Napo Pharmaceuticals Inc. from May 2, 2002 to July 7, 2006. He served as an Executive Director of Intrabiotics Pharmaceuticals Inc. since December 22, 2006. He served as a Director of the La Jolla Laboratories. Dr. Quart received a Pharm.D. in clinical pharmacy from the University of California, San Francisco.Read Full Background




Corporate Headquarters
4242 Campus Point CourtSan Diego, California 92121United StatesPhone: 858-251-4400Fax: --
Board Members Memberships
DirectorNeuroGenetic Pharmaceuticals, Inc.2006-PresentDirectorArdea Biosciences, Inc.2012-PresentChief Executive Officer & DirectorHeron Therapeutics, Inc.
Education
Doctorate University of California-San Francisco
Other Affiliations
Agouron Pharmaceuticals, Inc.Synageva BioPharma Corp.Intrabiotics Pharmaceuticals Inc.Trimeris IncEastman Kodak CompanyUniversity of California-San FranciscoNapo Pharmaceuticals, Inc.Ardea Biosciences, Inc.NeuroGenetic Pharmaceuticals, Inc.


Annual Compensation
Salary$579,143Total Annual Compensation$579,143
Stocks Options
All Other Compensation$7,950Exercised Options$8,102Exercised Options Value$76,262Exercisable Options$845,927Exercisable Options Value$3,965,054Unexercisable Options$743,106Unexercisable Options Value$1,135,950Total Value of Options$7,389,766Total Number of Options$1,972,135
Total Compensation
Total Annual Cash Compensation$795,585Total Short Term Compensation$579,143Other Long Term Compensation$7,950Total Calculated Compensation$3,772,329




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Heron Therapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close



































Barry D. Quart Pharm.D. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Barry D. Quart Pharm.D.
Dir., Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer at Heron Therapeutics, Inc.


View Full Profile
Are you Barry D. Quart Pharm.D.? Claim your profile


 


Sign up for Equilar Atlas and view Barry D. Quart Pharm.D.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Barry D. Quart Pharm.D.'s  network and community.
												FOLLOW changes in Barry D. Quart Pharm.D.'s employment and money-in-motion.
												CONNECT with Barry D. Quart Pharm.D. through your network of contacts.
												








Barry D. Quart Pharm.D.'s Executive Work History


Current


Dir., Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer, 
Heron Therapeutics, Inc.


Past
To view Barry D. Quart Pharm.D.'s complete executive work history, sign up now
Age
60

 
 


Barry D. Quart Pharm.D.'s Biography



Barry D. Quart, Pharm.D. has served as a director of Heron since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through May 2013 and as a director through its acquisition by AstraZeneca PLC in June 2012. Previously, he was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Developme ...
(Read More)

			Barry D. Quart, Pharm.D. has served as a director of Heron since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through May 2013 and as a director through its acquisition by AstraZeneca PLC in June 2012. Previously, he was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer's La Jolla Laboratories. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from June 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in June 2015. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco. Dr. Quart's qualifications to serve on our Board include his experience in senior management and as a director with other biotechnology and pharmaceutical companies and his prior drug development experience.
		
Source: Heron Therapeutics, Inc. on 04/26/2017
		
	

 






Sign up for Equilar Atlas and view Barry D. Quart Pharm.D.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Barry D. Quart Pharm.D.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Barry D. Quart Pharm.D.'s  network and community.
												FOLLOW changes in Barry D. Quart Pharm.D.'s employment and money-in-motion.
												CONNECT with Barry D. Quart Pharm.D. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Barry D. Quart Pharm.D.


















Barry D. Quart Pharm.D.'s Connections (61)





Sign up now to view Barry D. Quart Pharm.D.'s 61 connections »









Srinivas Akkaraju
Board Member, Seattle Genetics, Inc.









David T. Hagerty
Executive Vice President, Clinical Development, Conatus Pharmaceuticals Inc.









Henry J. Fuchs
President, Worldwide Research and Development, BioMarin Pharmaceutical Inc.









Stephen R. Davis
Dir., President and Chief Executive Officer, ACADIA Pharmaceuticals Inc.









Mark A. Goldberg
Board Member, ImmunoGen, Inc.









Brian G. Drazba
Former Vice President, Finance and Chief Financial Officer, Heron Therapeutics, Inc.









Kimberly J. Manhard
Executive Vice President, Drug Development, Heron Therapeutics, Inc.









Wendy L. Dixon
Board Member, Incyte Corporation









John B. Whelan
Former President, Chief Executive Officer and Chief Financial Officer, Heron Therapeutics, Inc.









Kevin C. Tang
Chairman of the Board, Heron Therapeutics, Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993
















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft




















 





HRTX Barry D. Quart Insider Trades for Heron Therapeutics Inc.


































Bulletin

Merck profit and sales top expectations amid big jump in Keytruda sales »
        




Investor Alert







New York Markets Open in:



Market Snapshot
Analyst Ratings


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Heron Therapeutics Inc.

                  NASDAQ: HRTX
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Heron Therapeutics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 27, 2017, 5:09 p.m.


HRTX

/quotes/zigman/28133492/composite


$
17.15




Change

+0.75
+4.57%

Volume
Volume 29,668
Quotes are delayed by 20 min








/quotes/zigman/28133492/composite
Previous close

$
			17.15
		


$
				16.40
			
Change

-0.75
-4.37%





Day low
Day high
$16.35
$17.25










52 week low
52 week high

            $12.21
        

            $24.00
        


















Insider Activity


Individual




Barry D. Quart



Dr. Barry D. Quart is Chief Executive Officer & Director at Heron Therapeutics, Inc. He  is on the Board of Directors at Heron Therapeutics, Inc. and NeuroGenetic Pharmaceuticals, Inc. 
Dr. Quart was previously employed as Independent Director by Synageva BioPharma Corp., President, Chief Executive Officer & Director by Ardea Biosciences, Inc., President by PS Pharmaceuticals, Inc., President-Research & Development by Agouron Pharmaceuticals, Inc., Director, SVP-Global Research & Development by Pfizer (La Jolla), and Senior Vice President by Pfizer Global Research & Development. He also served on the board at Trimeris, Inc. 
He received his doctorate degree from The University of California, San Francisco. 



Transactions


Date
Shares
Transaction
Value





07/19/2016
4,630


 
Derivative/Non-derivative trans. at $7.2 per share.


33,336


04/29/2016
837


 



15,250


03/02/2016
3,472


 
Derivative/Non-derivative trans. at $7.2 per share.


24,998


12/29/2015
25,000


 
Gift at $0 per share.


0


12/28/2015
2,315


 
Derivative/Non-derivative trans. at $7.2 per share.


16,668


10/14/2015
10,000


 
Derivative/Non-derivative trans. at $7.2 per share.


72,000


09/29/2015
14,306


 
Derivative/Non-derivative trans. at $7.2 per share.


103,003


08/18/2015
10,000


 
Derivative/Non-derivative trans. at $7.2 per share.


72,000


04/30/2015
2,881


 



21,895


03/02/2015
10,000


 
Disposition at $13.07 per share.


130,700


12/12/2014
10,000


 
Gift at $0 per share.


0


12/12/2014
928


 
Gift at $0 per share.


0


10/31/2014
1,941


 



14,557


06/25/2014
10,000


 
Acquisition at $11.75 per share.


117,500


11/20/2013
1,000,000


 
Acquisition at $0.4 per share.


400,000





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Kevin C. Tang 
Chairman




Mr. Robert H. Rosen 
President, Director & Chief Commercial Officer




Dr. Barry D. Quart 
Chief Executive Officer & Director




Mr. Robert E. Hoffman 
Chief Financial Officer & Senior VP-Finance




Dr. Thomas B. Ottoboni 
SVP-Pharmaceutical, Research & Development




Ms. Kimberly J. Manhard 
Executive Vice President-Drug Development




Mr. Christian  Waage 
Director




Mr. Daniel  Martin 
Vice President-Marketing




Mr. David L. Szekeres 
Secretary, Senior VP, General Counsel & IR Contact




Mr. Sean T. Ristine 
Vice President-Human Resources




Mr. John W. Poyhonen 
Independent Director




Mr. Craig A. Johnson 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




7:23 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Pre


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
7:20aCan Snap fall even more as lockups expire?
7:19aChip stocks are cool again, but reality is here
7:19aWhere to get Chipotle queso: check out this interactive map
7:19aAaron's acquires its largest franchisee in all-cash deal
7:18aExpedia stock price target raised to $173 from $158 at Piper Jaffray
7:17aA provocative new analysis suggests you don’t have to take all your antibiotics after all
7:17aA case for buying the freakin’ dip with Amazon, as the Mooch might now say
7:17aPriceline stock price target raised to $2,150 from $1,900 at Piper Jaffray
7:15aSJW Group upgraded to buy from neutral at Janney
7:15aVF Corp. stock price target raised to $70 from $53 at Susquehanna Financial
7:15aDollar spins wheels ahead of GDP report expected to show faster clip of growth
7:14aVF Corp. upgraded to positive from neutral at Susquehanna Financial
7:13aTeradyne upgraded to overweight from sector weight at KeyBanc Capital
7:13aLogMeIn upgraded to overweight from sector weight at KeyBanc Capital
7:11aTwitter stock price target raised to $14 from $13 at RBC Capital
7:08aCoca-Cola Zero Sugar sparks analyst optimism, but other factors could stifle growth
7:06aIntel stock price target raised to $39 from $38 at SunTrust RH
7:06aMasterCard stock price target raised to $145 from $135 at SunTrust RH
7:05aCharter Communications stock price target raised to $400 from $380 at SunTrust RH
7:04aWhy the GDP report may show U.S. economy growing twice as fast
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,796.55

+85.54
+0.39%





nasdaq

/quotes/zigman/12633936/realtime
6,382.19

-40.56
-0.63%





s&p 500

/quotes/zigman/3870025/realtime
2,475.42

-2.41
-0.10%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

































































Board of Directors | Heron Therapeutics
































Skip to main content












  












Search form






 





























Home About Heron Board of Directors 





















Menu

Home
About HeronCompany Overview
Grants, Sponsorships, and Charitable Giving
Management
Board of Directors
Compliance
Contact Us
Careers

Our Focus
Product Portfolio
Patient/​Investigator Resources
Investor Resources
 























Board of Directors
Kevin C. TangChairman
Barry D. Quart, Pharm.D.Chief Executive Officer and Director
Robert H. RosenPresident and Director
Craig A. JohnsonDirector
John W. PoyhonenDirector
Christian WaageDirector

Kevin C. TangChairman
Kevin C. Tang has served as director of Heron since February 2009 and as Chairman since July 2012. Mr. Tang has more than 20 years of experience evaluating, creating and building biotechnology companies that are focused on developing treatments for life-threatening and debilitating diseases and conditions. Mr. Tang is the President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm's Life Sciences research group. Since August 2014, Mr. Tang has served as a director and the Chairman of La Jolla Pharmaceutical Company. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in June 2012. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, he served as a director of Penwest Pharmaceuticals Co. From 2001 to 2008, he was a director of Trimeris, Inc. (acquired by Synageva Biopharma Corp.). Mr. Tang received a B.S. degree from Duke University.
Back to top

Barry D. Quart, Pharm.D.Chief Executive Officer and Director
Barry D. Quart, Pharm.D. has served as a director of Heron since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through May 2013 and as a director through its acquisition by AstraZeneca PLC in June 2012. Previously, he was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer's La Jolla Laboratories. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from June 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in June 2015. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.
Back to top

Robert H. RosenPresident and Director
Robert H. Rosen has served as a director of Heron since July 2012. Mr. Rosen was appointed President in May 2013 and prior to that served as our Senior Vice President and Chief Commercial Officer since October 2012. Mr. Rosen has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and commercializing pharmaceutical products. From March 2012 to October 2012, Mr. Rosen served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. From April 2011 to March 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals, where he was responsible for the development of the oncology business unit for regions that included the Americas, Europe, Japan and Asia Pacific. During his tenure at Bayer, Mr. Rosen led the launch of Nexavar®(sorafenib) for the treatment of renal cell carcinoma and hepatocellular carcinoma. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc., where he was responsible for the development of Sanofi's U.S. oncology business and the launch of Eloxatin® (oxaliplatin) for colon cancer. Mr. Rosen has been a director of La Jolla Pharmaceutical Company since July 2014. From November 2014 to December 2015, Mr. Rosen served as a director of Conkwest, Inc. (now NantKwest, Inc.). Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.
Back to top

Craig A. JohnsonDirector
Craig A. Johnson has served as a director of Heron since January 2014. Mr. Johnson has more than 25 years of experience serving in senior financial management roles and governing corporations, primarily in the biotechnology industry. Since 2013, Mr. Johnson has served as a director of Mirati Therapeutics, Inc. and La Jolla Pharmaceutical Company. Since 2015, Mr. Johnson has served as a director of GenomeDx Biosciences, Inc. Mr. Johnson served as a director of Ardea Biosciences, Inc. from 2008 through its acquisition by AstraZeneca PLC in June 2012. From 2011 to 2014, Mr. Johnson served as a director of Adamis Pharmaceuticals Corporation. From 2011 to 2012, he was Chief Financial Officer of PURE Bioscience, Inc. From 2010 to 2011, Mr. Johnson was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. From 1994 to 2004, Mr. Johnson held various positions at MitoKor, Inc., most recently as Chief Financial Officer and Senior Vice President of Operations. Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received a B.B.A. degree in accounting from the University of Michigan-Dearborn.
Back to top

John W. PoyhonenDirector
John W. Poyhonen has served as a director of Heron since January 2014. Mr. Poyhonen has more than 25 years of experience serving in leadership positions in biotechnology, pharmaceutical and food ingredient companies and commercializing innovative products. Mr. Poyhonen is currently the President, Chief Executive Officer and a director of Senomyx, Inc. He joined Senomyx in 2003 as Vice President and Chief Business Officer; was promoted in 2004 to Vice President and Chief Financial and Business Officer; was named Senior Vice President, Chief Financial and Business Officer in 2006; was promoted to President and Chief Operating Officer in 2009; and promoted to his current role in January 2014. From 1996 to 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., most recently as Vice President of National Sales. Prior to holding this position, Mr. Poyhonen served as Vice President of Marketing and Vice President of National Accounts. He was previously a director of Ardea Biosciences, Inc. from 2007 through its acquisition by AstraZeneca PLC in June 2012. Mr. Poyhonen received a B.A. degree in marketing from Michigan State University and a M.B.A. degree from the University of Kansas.
Back to top

Christian WaageDirector
Christian Waage has served as a director of Heron since June 2016. Mr. Waage has more than 15 years of regulatory, legal, and financial transaction experience primarily in the biotechnology industry. Mr. Waage currently serves as Managing Director at Receptos, a wholly owned subsidiary of Celgene Corporation. Mr. Waage joined Receptos in December 2013 as Senior Vice President and General Counsel and played an instrumental role in its acquisition by Celgene for $7.2B in August 2015. Prior to Receptos, he served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. from July 2012 until its acquisition by Vista Equity Partners for $1B in August 2013. In addition to overseeing its acquisition, his responsibilities at Websense included all legal affairs, including SEC reporting and compliance, corporate governance, litigation and licensing operations. Prior to Websense, Mr. Waage served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. from March 2008 until its acquisition by AstraZeneca PLC for $1.3B in July 2012. Prior to Ardea Biosciences, Mr. Waage practiced law for over a decade at DLA Piper, where he was a partner. Mr. Waage received a J.D. from the University of San Diego School of Law and a B.A. degree in Economics from the University of California, San Diego.
Back to top
 

 






















Home
About Heron
Our Focus
Product Portfolio
Patient/​Investigator Resources
Investor Resources
Site Map
Terms of Use
Privacy Statement
Careers
 



© 2017 Heron Therapeutics, Inc. All Rights Reserved.

























Management | Heron Therapeutics
































Skip to main content












  












Search form






 





























Home About Heron Management 





















Menu

Home
About HeronCompany Overview
Grants, Sponsorships, and Charitable Giving
Management
Board of Directors
Compliance
Contact Us
Careers

Our Focus
Product Portfolio
Patient/​Investigator Resources
Investor Resources
 























Management
Barry D. Quart, Pharm.D.Chief Executive Officer and Director
Robert H. RosenPresident and Director
Robert E. HoffmanChief Financial Officer and Senior VP, Finance
Kimberly J. ManhardExecutive VP, Drug Development
Thomas B. Ottoboni, Ph.D.Senior VP, Pharmaceutical and Preclinical Research and Development
David L. SzekeresSenior VP, General Counsel, Business Development and Corporate Secretary
Sean T. RistineVP, Human Resources

Barry D. Quart, Pharm.D.Chief Executive Officer and Director
Barry D. Quart, Pharm.D. has served as a director of Heron since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through May 2013 and as a director through its acquisition by AstraZeneca PLC in June 2012. Previously, he was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer's La Jolla Laboratories. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from June 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in June 2015. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.
Back to top

Robert H. RosenPresident and Director
Robert H. Rosen has served as a director of Heron since July 2012. Mr. Rosen was appointed President in May 2013, and prior to that, served as our Senior Vice President and Chief Commercial Officer since October 2012. Mr. Rosen has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and commercializing pharmaceutical products. From March 2012 to October 2012, Mr. Rosen served as Managing Partner of Scotia Nordic LLC, a life science advisory firm. From April 2011 to March 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals, where he was responsible for the development of the oncology business unit for regions that included the Americas, Europe, Japan and Asia Pacific. During his tenure at Bayer, Mr. Rosen led the launch of Nexavar® (sorafenib) for the treatment of renal cell carcinoma and hepatocellular carcinoma. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc., where he was responsible for the development of Sanofi's U.S. oncology business and the launch of Eloxatin® (oxaliplatin) for colon cancer. Mr. Rosen has been a director of La Jolla Pharmaceutical Company since July 2014. From November 2014 to December 2015, Mr. Rosen served as a director of Conkwest, Inc. (now NantKwest, Inc.). Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.
Back to top

Robert E. HoffmanChief Financial Officer and Senior VP, Finance
Robert E. Hoffman joined us as Chief Financial Officer and Senior Vice President, Finance in April 2017. Prior to joining Heron, Mr. Hoffman served as Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals, Inc., a biopharmaceutical company, since September 2016. Prior to Innovus Pharmaceuticals, Inc., Mr. Hoffman was Chief Financial Officer of AnaptysBio, Inc., a biopharmaceutical company, from July 2015 until September 2016. He was part of the founding management team of Arena Pharmaceuticals, Inc. in 1997, a biopharmaceutical company, ultimately serving as Senior Vice President, Finance and Chief Financial Officer until March 2011, and then again from August 2011 until July 2015. From March 2011 to August 2011, he served as Chief Financial Officer for Polaris Group, a biopharmaceutical company. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, Kura Oncology, Inc., a biopharmaceutical company, and MabVax Therapeutics Holdings, Inc., a biopharmaceutical company. He also is a member of the Financial Accounting Standards Board’s Small Business Advisory Committee and is a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman received his B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.
Back to top

Kimberly J. ManhardExecutive VP, Drug Development
Kimberly J. Manhard joined us as Executive Vice President, Drug Development in January 2016. Ms. Manhard served as a director of Heron from January 2014 until she joined the management team. Ms. Manhard has more than 25 years of experience in drug development, regulatory affairs and pharmaceutical operations. From May 2008 to January 2016, Ms. Manhard served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., a wholly-owned subsidiary of AstraZeneca PLC. In her role at Ardea, Ms. Manhard was instrumental in the development and December 2015 regulatory approval of Zurampic® (lesinurad) for the treatment of hyperuricemia associated with gout. Prior to joining Ardea in 2006, Ms. Manhard was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc. and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including Viracept® (nelfinavir). She was also previously with Bristol Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol® (paclitaxel) and infectious disease compounds, including Videx® (didanosine) and Zerit® (stavudine). Ms. Manhard began her industry career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance, Inc.). Ms. Manhard recieved a B.S. degree in zoology and a B.A. degree in French from the University of Florida.
Back to top

Thomas B. Ottoboni, Ph.D.Senior VP, Pharmaceutical and Preclinical Research and Development
Thomas B. Ottoboni, Ph.D. joined us as Vice President of Pharmaceutical Development in March 2012 and was promoted to Senior Vice President of Pharmaceutical and Preclinical Research and Development in July 2014. Dr. Ottoboni has more than 20 years of drug development experience. From 2010 until 2011, Dr. Ottoboni was Vice President of Research and Development at Talima Therapeutics, Inc., where he worked on the develpment of a drug delivery implant to treat onychomycosis. From 1996 to 2008, Dr. Ottoboni served as Executive Vice President of Strategy and Operations at POINT Biomedical Corp., where he developed several imaging and drug delivery systems. From May 1994 through July 1996, Dr. Ottoboni served as Manager of Systems Development and Drug Delivery Research for InSite Vision, Inc., where he developed ophthalmic pharmaceutical delivery systems. He previously served as Director of Drug Delivery at Vitaphore Corp. Dr. Ottoboni is an inventor on more than 20 U.S. patents in organic and macromolecular chemistry. He received a B.S. degree in chemistry and a Ph.D. in organic chemistry from the University of California, Berkeley.
Back to top

David L. SzekeresSenior VP, General Counsel, Business Development and Corporate Secretary
David L. Szekeres joined us as Senior Vice President, General Counsel, Business Development and Corporate Secretary in March 2016. Mr. Szekeres has more than 15 years of legal and industry experience. From February 2014 to December 2015, Mr. Szekeres served as General Counsel, Chief Business Officer, Principal Financial Officer, and Corporate Secretary at Regulus Therapeutics, Inc. In that role, Mr. Szekeres played a critical role in overseeing the company’s business, financial and legal responsibilities as it developed into a clinical-stage corporation. From 2008 through its acquisition by Thermo Fisher Scientific Inc. in 2014, Mr. Szekeres served as Deputy General Counsel, Chief Mergers and Acquisitions Counsel and Assistant Corporate Secretary at Life Technologies Corporation. From 2001 to 2006, Mr. Szekeres served as Corporate Attorney at a number of law firms, including O’Melveny & Myers LLP and Latham & Watkins LLP. Prior to 2001, Mr. Szekeres served as Senior Associate in Investment Banking at investment bank Robertson Stephens. Mr. Szekeres received a B.A. degree from the University of California, Irvine and a J.D. degree from Duke University School of Law.
Back to top

Sean T. Ristine VP, Human Resources
Sean T. Ristine joined us as Senior Director of Human Resources in August 2014 and was promoted to Vice President of Human Resources in September 2015. Mr. Ristine has more than 20 years of experience in human resources and business leadership. From September 2009 to August 2014, Mr. Ristine held key Human Resources positions at Cadence Pharmaceuticals, Inc., most recently as Senior Director of Human Resources and was instrumental in that function as Cadence grew to a commercial-stage company with over 200 employees located throughout the U.S. From 2004 through 2009, Mr. Ristine held Human Resources management roles of increasing responsibility at Kyocera Wireless Corp., including Director of Human Resources and Facilities. Prior to this, from 1995 to 2004, Mr. Ristine held positions at Kyocera America, Inc. including Manager of Human Resources. Mr. Ristine received a B.S. degree in Business and Organization Behavior from Brigham Young University and an M.B.A degree with an emphasis in Human Resources Management from San Diego State University.
Back to top
 

 






















Home
About Heron
Our Focus
Product Portfolio
Patient/​Investigator Resources
Investor Resources
Site Map
Terms of Use
Privacy Statement
Careers
 



© 2017 Heron Therapeutics, Inc. All Rights Reserved.

























Contact Us | Heron Therapeutics
































Skip to main content












  












Search form






 





























Home About Heron Contact Us 





















Menu

Home
About HeronCompany Overview
Grants, Sponsorships, and Charitable Giving
Management
Board of Directors
Compliance
Contact Us
Careers

Our Focus
Product Portfolio
Patient/​Investigator Resources
Investor Resources
 























Contact Us
Contact Information
To report an adverse event or product complaint: Call: 844-HERON11 (844-437-6611)Email: medinfo@herontx.com

General Information
844-HERON11 (844-437-6611)info@herontx.com
Career Inquiries
jobs@herontx.com
Corporate Contact / Business Development
bd@herontx.com
Investor & Media Relations
ir@herontx.com
Corporate Offices
Redwood City Office
123 Saginaw DriveRedwood City, CA 94063650-366-2626
San Diego Office
4242 Campus Point Court, Suite 200San Diego, CA 92121858-251-4400
Jersey City Office
101 Hudson Street, Suite 2100Jersey City, NJ 07302201-633-6473
Transfer Agent
Inquiries related to stock and transfer requirements, including lost stock certificates and changes of name or address, should be directed to our Transfer Agent.
Computershare
211 Quality Circle, Suite 210College Station, TX 77845800-962-4284www.computershare.com/investor
 

 






















Home
About Heron
Our Focus
Product Portfolio
Patient/​Investigator Resources
Investor Resources
Site Map
Terms of Use
Privacy Statement
Careers
 



© 2017 Heron Therapeutics, Inc. All Rights Reserved.

























Board of Directors | Heron Therapeutics
































Skip to main content












  












Search form






 





























Home About Heron Board of Directors 





















Menu

Home
About HeronCompany Overview
Grants, Sponsorships, and Charitable Giving
Management
Board of Directors
Compliance
Contact Us
Careers

Our Focus
Product Portfolio
Patient/​Investigator Resources
Investor Resources
 























Board of Directors
Kevin C. TangChairman
Barry D. Quart, Pharm.D.Chief Executive Officer and Director
Robert H. RosenPresident and Director
Craig A. JohnsonDirector
John W. PoyhonenDirector
Christian WaageDirector

Kevin C. TangChairman
Kevin C. Tang has served as director of Heron since February 2009 and as Chairman since July 2012. Mr. Tang has more than 20 years of experience evaluating, creating and building biotechnology companies that are focused on developing treatments for life-threatening and debilitating diseases and conditions. Mr. Tang is the President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm's Life Sciences research group. Since August 2014, Mr. Tang has served as a director and the Chairman of La Jolla Pharmaceutical Company. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in June 2012. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, he served as a director of Penwest Pharmaceuticals Co. From 2001 to 2008, he was a director of Trimeris, Inc. (acquired by Synageva Biopharma Corp.). Mr. Tang received a B.S. degree from Duke University.
Back to top

Barry D. Quart, Pharm.D.Chief Executive Officer and Director
Barry D. Quart, Pharm.D. has served as a director of Heron since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through May 2013 and as a director through its acquisition by AstraZeneca PLC in June 2012. Previously, he was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer's La Jolla Laboratories. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from June 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in June 2015. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.
Back to top

Robert H. RosenPresident and Director
Robert H. Rosen has served as a director of Heron since July 2012. Mr. Rosen was appointed President in May 2013 and prior to that served as our Senior Vice President and Chief Commercial Officer since October 2012. Mr. Rosen has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and commercializing pharmaceutical products. From March 2012 to October 2012, Mr. Rosen served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. From April 2011 to March 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals, where he was responsible for the development of the oncology business unit for regions that included the Americas, Europe, Japan and Asia Pacific. During his tenure at Bayer, Mr. Rosen led the launch of Nexavar®(sorafenib) for the treatment of renal cell carcinoma and hepatocellular carcinoma. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc., where he was responsible for the development of Sanofi's U.S. oncology business and the launch of Eloxatin® (oxaliplatin) for colon cancer. Mr. Rosen has been a director of La Jolla Pharmaceutical Company since July 2014. From November 2014 to December 2015, Mr. Rosen served as a director of Conkwest, Inc. (now NantKwest, Inc.). Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.
Back to top

Craig A. JohnsonDirector
Craig A. Johnson has served as a director of Heron since January 2014. Mr. Johnson has more than 25 years of experience serving in senior financial management roles and governing corporations, primarily in the biotechnology industry. Since 2013, Mr. Johnson has served as a director of Mirati Therapeutics, Inc. and La Jolla Pharmaceutical Company. Since 2015, Mr. Johnson has served as a director of GenomeDx Biosciences, Inc. Mr. Johnson served as a director of Ardea Biosciences, Inc. from 2008 through its acquisition by AstraZeneca PLC in June 2012. From 2011 to 2014, Mr. Johnson served as a director of Adamis Pharmaceuticals Corporation. From 2011 to 2012, he was Chief Financial Officer of PURE Bioscience, Inc. From 2010 to 2011, Mr. Johnson was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. From 1994 to 2004, Mr. Johnson held various positions at MitoKor, Inc., most recently as Chief Financial Officer and Senior Vice President of Operations. Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received a B.B.A. degree in accounting from the University of Michigan-Dearborn.
Back to top

John W. PoyhonenDirector
John W. Poyhonen has served as a director of Heron since January 2014. Mr. Poyhonen has more than 25 years of experience serving in leadership positions in biotechnology, pharmaceutical and food ingredient companies and commercializing innovative products. Mr. Poyhonen is currently the President, Chief Executive Officer and a director of Senomyx, Inc. He joined Senomyx in 2003 as Vice President and Chief Business Officer; was promoted in 2004 to Vice President and Chief Financial and Business Officer; was named Senior Vice President, Chief Financial and Business Officer in 2006; was promoted to President and Chief Operating Officer in 2009; and promoted to his current role in January 2014. From 1996 to 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., most recently as Vice President of National Sales. Prior to holding this position, Mr. Poyhonen served as Vice President of Marketing and Vice President of National Accounts. He was previously a director of Ardea Biosciences, Inc. from 2007 through its acquisition by AstraZeneca PLC in June 2012. Mr. Poyhonen received a B.A. degree in marketing from Michigan State University and a M.B.A. degree from the University of Kansas.
Back to top

Christian WaageDirector
Christian Waage has served as a director of Heron since June 2016. Mr. Waage has more than 15 years of regulatory, legal, and financial transaction experience primarily in the biotechnology industry. Mr. Waage currently serves as Managing Director at Receptos, a wholly owned subsidiary of Celgene Corporation. Mr. Waage joined Receptos in December 2013 as Senior Vice President and General Counsel and played an instrumental role in its acquisition by Celgene for $7.2B in August 2015. Prior to Receptos, he served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. from July 2012 until its acquisition by Vista Equity Partners for $1B in August 2013. In addition to overseeing its acquisition, his responsibilities at Websense included all legal affairs, including SEC reporting and compliance, corporate governance, litigation and licensing operations. Prior to Websense, Mr. Waage served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. from March 2008 until its acquisition by AstraZeneca PLC for $1.3B in July 2012. Prior to Ardea Biosciences, Mr. Waage practiced law for over a decade at DLA Piper, where he was a partner. Mr. Waage received a J.D. from the University of San Diego School of Law and a B.A. degree in Economics from the University of California, San Diego.
Back to top
 

 






















Home
About Heron
Our Focus
Product Portfolio
Patient/​Investigator Resources
Investor Resources
Site Map
Terms of Use
Privacy Statement
Careers
 



© 2017 Heron Therapeutics, Inc. All Rights Reserved.














